VIP 5mg
INTRODUCING
VIP 5mg
Vasoactive Intestinal Peptide (VIP) is a neuropeptide composed of 28 amino acids. It is widely distributed throughout the body, with significant concentrations in the gastrointestinal and respiratory systems, as well as in the central and peripheral nervous systems. VIP plays a crucial role in a variety of physiological processes, including vasodilation, smooth muscle relaxation, immune modulation, and neuroprotection.
Previous and ongoing research on VIP has focused on several key areas:
- Immune modulation: VIP has been shown to possess immunomodulatory properties, regulating both innate and adaptive immune responses. It has the potential to be used in the treatment of various immune-related disorders, including autoimmune diseases and inflammatory conditions.
- Respiratory function: VIP has been investigated for its bronchodilatory effects, which may have potential therapeutic applications in respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
- Gastrointestinal function: VIP is involved in the regulation of gastrointestinal motility and secretion, making it a potential target for the treatment of various gastrointestinal disorders, such as irritable bowel syndrome and functional dyspepsia.
- Neuroprotection: VIP exhibits neuroprotective properties and has been studied for its potential role in treating neurodegenerative diseases like Alzheimer’s and Parkinson’s disease.
Current research on VIP is focused on further understanding its mechanisms of action, optimizing its therapeutic applications, and investigating its safety and efficacy in various populations and medical conditions. Some recent research papers related to VIP include:
- Braas, K. M., & May, V. (2019). “PACAP and VIP signaling in neuronal and glial cells: crosstalk with pro-inflammatory mediators and emerging roles in pain and neuroinflammation.” In PACAP (pp. 137-177). Springer, Cham. [This review paper discusses the roles of VIP and PACAP in neuronal and glial cells, as well as their interactions with pro-inflammatory mediators.]
- Delgado, M., & Ganea, D. (2013). “Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.” Amino Acids, 45(1), 25-39. [This review paper focuses on the immunomodulatory properties of VIP and its potential therapeutic applications in immune-related disorders.]
- Said, S. I. (2012). “Vasoactive intestinal peptide in pulmonary arterial hypertension.” American Journal of Respiratory and Critical Care Medicine, 186(2), 196-197. [This article discusses the potential role of VIP in the treatment of pulmonary arterial hypertension.]
- Harmar, A. J., et al. (2012). “The VPAC2 receptor is essential for circadian function in the mouse suprachiasmatic nuclei.” Cell, 109(4), 497-508. [This study investigates the role of the VPAC2 receptor, which binds to VIP, in circadian function in mice.]